other material
confidence high
sentiment positive
materiality 0.80
MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia
MeiraGTx Holdings plc
- 62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.
- Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.
- No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.
- Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients.